Chemomab Therapeutics (CMMB)
(Delayed Data from NSDQ)
$1.16 USD
+0.04 (3.57%)
Updated Jul 22, 2024 03:59 PM ET
After-Market: $1.16 0.00 (0.00%) 4:26 PM ET
2-Buy of 5 2
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.16 USD
+0.04 (3.57%)
Updated Jul 22, 2024 03:59 PM ET
After-Market: $1.16 0.00 (0.00%) 4:26 PM ET
2-Buy of 5 2
D Value B Growth D Momentum C VGM
Zacks News
Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Chemomab Therapeutics (CMMB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Here's Why Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Chemomab Therapeutics Ltd. Sponsored ADR (CMMB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC
by Zacks Equity Research
The FDA bestows Fast Track designation to Chemomab's (CMMB) pipeline candidate, CM-101, for the treatment of primary sclerosing cholangitis. Stock rises.
Intercept's (ICPT) NDA for NASH Treatment Accepted By FDA
by Zacks Equity Research
Intercept's (ICPT) new drug application (NDA) for obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis gets accepted by the regulatory body in the United States.
Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why
by Zacks Equity Research
Intercept (ICPT) gains 12% in the last six months on Ocaliva's positive performance and encouraging pipeline progress.
The Zacks Analyst Blog Highlights Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax
by Zacks Equity Research
Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax are included in this Analyst Blog.
Biotech Stock Roundup: GERN Surges on Study Data, PHAT, VERA Offer Updates & More
by Zacks Equity Research
Updates from Geron (GERN) and VERA are the key highlights from the biotech sector during the past week.
Chemomab (CMMB) Mid-Stage Study for NASH Meets Primary Goal
by Zacks Equity Research
Chemomab's (CMMB) phase II study evaluating CM-101 in NASH patients met its primary endpoint of safety and tolerability.
New Strong Sell Stocks for March 14th
by Zacks Equity Research
AVYA, BGS, and CMMB have been added to the Zacks Rank #5 (Strong Sell) List on March 14, 2022.